BioCardia, Inc. Common Stock
BCDA Real Time Price USDRecent trades of BCDA by members of U.S. Congress
No Congress Trading data for this ticker
Congress Trading Dashboard
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by BCDA's directors and management
Government lobbying spending instances
No Corporate Lobbying instances for this ticker
Corporate Lobbying DashboardEstimated quarterly lobbying spending
No Corporate Lobbying data for this ticker
Corporate Lobbying DashboardNew patents grants
-
Patent Title: Method of accessing the left atrium with a multi-directional steerable catheter Jul. 16, 2024
-
Patent Title: Radial and trans-endocardial delivery catheter May. 21, 2024
-
Patent Title: Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies Nov. 28, 2023
-
Patent Title: Bone marrow derived neurokinin-1 receptor positive (nk1r+) mesenchymal stem cells for therapeutic applications May. 09, 2023
-
Patent Title: Multi-directional steerable catheter Apr. 04, 2023
-
Patent Title: Target site selection, entry and update with automatic remote image annotation Jun. 14, 2022
-
Patent Title: Multi-directional steerable catheter Oct. 12, 2021
-
Patent Title: Devices and methods for accessing the vasculature of a patient Dec. 29, 2020
-
Patent Title: Radial and trans-endocardial delivery catheter Sep. 22, 2020
-
Patent Title: Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies Dec. 31, 2019
-
Patent Title: Radial and trans-endocardial delivery catheter Sep. 11, 2018
-
Patent Title: Method of preparing autologous cells and methods of use for therapy Jul. 31, 2018
-
Patent Title: Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies Apr. 17, 2018
-
Patent Title: Steerable endoluminal devices and methods Oct. 03, 2017
-
Patent Title: Method of preparing autologous cells and methods of use for therapy Sep. 05, 2017
-
Patent Title: Treatment for chronic myocardial infarct Dec. 13, 2016
-
Patent Title: Treatment for chronic myocardial infarct Nov. 29, 2016
-
Patent Title: Method of preparing autologous cells and method of use for therapy Apr. 05, 2016
-
Patent Title: Method of accessing a contralateral femoral artery of a patient Jul. 14, 2015
-
Patent Title: Method of accessing a renal artery of a patient May. 05, 2015
-
Patent Title: Method of implanting a pfo occluder in a patient Apr. 28, 2015
-
Patent Title: Method of accessing a carotid artery of a patient Apr. 21, 2015
-
Patent Title: Steerable guide catheters and methods for their use Jan. 27, 2015
-
Patent Title: Implant delivery catheter system and methods for its use Sep. 10, 2013
-
Patent Title: Treatment for chronic myocardial infarction Jul. 30, 2013
-
Patent Title: System for treating the heart with potentially embolic agents through a right heart approach Mar. 05, 2013
-
Patent Title: Drug delivery catheters that attach to tissue and methods for their use Sep. 27, 2011
-
Patent Title: Method of treating coronary arteries with perivascular delivery of therapeutic agents Aug. 16, 2011
-
Patent Title: Catheter systems and methods for placing bi-ventricular pacing leads Nov. 23, 2010
-
Patent Title: Bio-interventional therapeutic treatments for cardiovascular diseases Jun. 15, 2010
Federal grants, loans, and purchases
No Government Contracts for this ticker
Government Contracts DashboardEstimated quarterly amount awarded from public contracts
Number of mentions of BCDA in WallStreetBets Daily Discussion
Recent insights relating to BCDA
Recent picks made for BCDA stock on CNBC
ETFs with the largest estimated holdings in BCDA
Shareholder
|
Shares Held
|
---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BCDA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.